IL298608A - Methods of treating aging-related disorders - Google Patents

Methods of treating aging-related disorders

Info

Publication number
IL298608A
IL298608A IL298608A IL29860822A IL298608A IL 298608 A IL298608 A IL 298608A IL 298608 A IL298608 A IL 298608A IL 29860822 A IL29860822 A IL 29860822A IL 298608 A IL298608 A IL 298608A
Authority
IL
Israel
Prior art keywords
methods
cells
related disorders
treating aging
tgf
Prior art date
Application number
IL298608A
Other languages
Hebrew (he)
Original Assignee
Hcw Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/035598 external-priority patent/WO2021247003A1/en
Application filed by Hcw Biologics Inc filed Critical Hcw Biologics Inc
Publication of IL298608A publication Critical patent/IL298608A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Claims (1)

1.Attorney Docket No. 47039-0022WO 193. The methods of claim 191, wherein the diseased cells include cancer cells, virally-infected cells, and intracellularly-bacterially-infected cells. 194. The methods of claim 191, wherein the infectious agents include virus, bacterium, fungus, and parasite. 195. One or more agent(s) that result(s) in a decrease in the activation of a TGF-β receptor for use in a method of killing or reducing the number of naturally-occurring and/or treatment-induced senescent cells in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of one or more agent(s) that result(s) in a decrease in the activation of a TGF-β receptor.
IL298608A 2020-06-01 2021-06-01 Methods of treating aging-related disorders IL298608A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063032933P 2020-06-01 2020-06-01
PCT/US2020/035598 WO2021247003A1 (en) 2020-06-01 2020-06-01 Methods of treating aging-related disorders
US202063118536P 2020-11-25 2020-11-25
PCT/US2021/035285 WO2021247604A1 (en) 2020-06-01 2021-06-01 Methods of treating aging-related disorders

Publications (1)

Publication Number Publication Date
IL298608A true IL298608A (en) 2023-01-01

Family

ID=76523519

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298608A IL298608A (en) 2020-06-01 2021-06-01 Methods of treating aging-related disorders

Country Status (7)

Country Link
EP (1) EP4157460A1 (en)
JP (1) JP2023527869A (en)
KR (1) KR20230031280A (en)
AU (1) AU2021283199A1 (en)
CA (1) CA3184756A1 (en)
IL (1) IL298608A (en)
WO (1) WO2021247604A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310164A (en) * 2021-08-11 2024-03-01 Hcw Biologics Inc Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
WO2023168363A1 (en) * 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
JP2001206899A (en) 1999-11-18 2001-07-31 Japan Tobacco Inc HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF
PT1345969E (en) 2000-12-26 2010-11-17 Inst Nat Sante Rech Med Anti-cd28 antibody
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US7482436B2 (en) 2002-08-30 2009-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of antibody
ES2559763T3 (en) 2002-09-10 2016-02-15 Affimed Gmbh CD3 specific human antibody with immunosuppressive properties
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
WO2004084835A2 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ATE531732T1 (en) 2004-03-30 2011-11-15 Yissum Res Dev Co BI-SPECIFIC ANTIBODIES TARGETING CELLS INVOLVED IN ALLERGIC-TYPE REACTIONS, COMPOSITIONS AND USES THEREOF
CA2604357C (en) 2005-04-26 2012-01-17 Pfizer Inc. P-cadherin antibodies
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PT2274008E (en) 2008-03-27 2014-05-12 Zymogenetics Inc Compositions and methods for inhibiting pdgfrbeta and vegf-a
HUE032894T2 (en) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies inhibiting vegf
SG192489A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
WO2010017103A2 (en) 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
BR112012008833A2 (en) 2009-10-15 2015-09-08 Abbott Lab double variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BR112012020101A2 (en) 2010-02-11 2018-09-25 Alexion Pharma Inc diagnostic and therapeutic methods using anti-cd200 antibodies.
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
MX341579B (en) 2010-08-03 2016-08-25 Abbvie Inc * Dual variable domain immunoglobulins and uses thereof.
JP2012034668A (en) 2010-08-12 2012-02-23 Tohoku Univ Fragment of humanized anti-egfr antibody substituted-lysine variable region, and use thereof
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
MX336197B (en) 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies.
WO2012147713A1 (en) 2011-04-25 2012-11-01 第一三共株式会社 Anti-b7-h3 antibody
MX347514B (en) 2011-05-25 2017-04-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders.
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
US9403911B2 (en) 2011-06-06 2016-08-02 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
BR112013032899A2 (en) 2011-06-22 2017-01-24 Inserm Inst Nat De La Santé Et De La Rech Médicale anti-axl antibodies and uses thereof
BR112014011331A2 (en) 2011-11-11 2017-04-25 Rinat Neuroscience Corp trop-2 specific antibodies and their uses
KR101535341B1 (en) 2012-07-02 2015-07-13 한화케미칼 주식회사 Novel monoclonal antibody that specifically binds to DLL4 and use thereof
KR20150038012A (en) 2012-08-08 2015-04-08 로슈 글리카트 아게 Interleukin-10 fusion proteins and uses thereof
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
EP2890713A1 (en) 2012-08-28 2015-07-08 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
TWI664192B (en) 2012-11-20 2019-07-01 法商賽諾菲公司 Anti-ceacam5 antibodies and uses thereof
ES2895848T3 (en) 2012-12-17 2022-02-22 Cell Medica Inc Antibodies against IL-1 beta
TW201446794A (en) 2013-02-20 2014-12-16 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
KR102127408B1 (en) 2014-01-29 2020-06-29 삼성전자주식회사 Anti-Her3 scFv fragment and Bispecific anti-c-Met/anti-Her3 antibodies comprising the same
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
FR3021970B1 (en) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille ANTIBODY AGAINST GALECTIN 9 AND INHIBITOR OF THE SUPPRESSIVE ACTIVITY OF T REGULATORY LYMPHOCYTES
AP2017009765A0 (en) 2014-08-19 2017-02-28 Merck Sharp & Dohme Anti-tigit antibodies
JP7211703B2 (en) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー Anti-MERTK agonist antibody and use thereof
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
BR112017022255A2 (en) 2015-04-17 2018-08-28 Centre Nat Rech Scient isolated humanized or human antibody, isolated nucleic acid molecule, vector, host cell, method for producing an antibody, and pharmaceutical composition
PL3328894T3 (en) 2015-08-06 2019-05-31 Agency Science Tech & Res Il2rbeta/common gamma chain antibodies
CR20180225A (en) 2015-09-25 2018-07-09 Genentech Inc ANTI-TIGIT ANTIBODY AND METHODS OF USE
WO2017083612A1 (en) 2015-11-13 2017-05-18 Dana-Farber Cancer Institute, Inc. An nkg2d-ig fusion protein for cancer immunotherapy
SG11201807437XA (en) 2016-03-01 2018-09-27 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Antibodies specific to human poliovirus receptor (pvr)
US11963980B2 (en) 2016-04-25 2024-04-23 Musc Foundation For Research Development Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
MX2019007981A (en) * 2017-01-03 2019-10-15 Bioatla Llc Protein therapeutics for treatment of senescent cells.
CA3074635A1 (en) * 2017-08-28 2019-03-07 Altor Bioscience Llc Il-15-based fusions to il-7 and il-21
AU2019328290A1 (en) * 2018-08-30 2021-02-25 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20210069639A (en) * 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. Single-chain chimeric polypeptides and uses thereof
EP3844182A1 (en) * 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof

Also Published As

Publication number Publication date
KR20230031280A (en) 2023-03-07
CA3184756A1 (en) 2021-12-09
JP2023527869A (en) 2023-06-30
EP4157460A1 (en) 2023-04-05
WO2021247604A1 (en) 2021-12-09
AU2021283199A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
IL298608A (en) Methods of treating aging-related disorders
MXPA05002791A (en) Non-sequence complementary antiviral oligonucleotides.
WO2002043652A3 (en) Anti-proliferative drugs
BR0209658A (en) 4-Amino-5-phenyl-7-1-cyclobutyl-pyrrolo [2,3-d] pyrimidine derivatives
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
CA2353553A1 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2004096224A3 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
BR0316157A (en) 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo [2,3-d] pyrimidine derivatives
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
PT1362600E (en) Topical use of nf-kb decoys for treating atopic dermatitis
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
EP4241855A3 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
CA2519789A1 (en) Aplidine for multiple myeloma treatment
CL2023000296A1 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
WO2003103699A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
WO2003103675A3 (en) Combination treatments for purinoceptor-related disorders
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Rafiq et al. Comparison of topical 0.03% tacrolimus with 0.05% clobetasol in treatment of vitiligo
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
BR0308756A (en) Combination comprising a cdk and doxorubicin inhibitor
MX2022002451A (en) Methods for treating cln2 disease in pediatric subjects.